Intravenous iron and safety: Is the end of the debate on the horizon?

Blood Transfusion

Volumn 12, Issue 3, 2014, Pages 287-289

  Munõz, Manuel ^a   Goḿez Ramírez, Susana ^b   Liumbruno, Giancarlo Maria ^c   Grazzini, Giuliano ^c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ALLERGIC REACTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDITORIAL; HUMAN; IRON THERAPY; PRACTICE GUIDELINE; TREATMENT INDICATION;

HUMANS; IRON;

EID: 84904631183     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2014.0144-14     Document Type: Editorial

References (19)

1. st century. Therap Adv Gastroenterol 2011; 4: 177-84.
2. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014; 123: 615-24.
3. Shander A, Javidroozi M, Ozawa S, Hare GM. What is really dangerous: anaemia or transfusion? Br J Anaesth 2011; 107 (Suppl 1): i41-i59.
4. Loor G, Rajeswaran J, Li L, et al. The least of 3 evils: exposure to red blood cell transfusion, anemia, or both? J Thorac Cardiovasc Surg 2013; 146: 1480-7.e6.
5. Shander A, Goodnough LT, Javidroozi M, et al. Iron deficiency anemia: bridging the knowledge and practice gap. Transfus Med Rev 2014; doi: 10.1016/j.tmrv.2014.05.001.
6. Liumbruno GM, Rafanelli D. Iron therapy: a piece in the puzzle of allogeneic blood saving strategies with a relevant role in patients' blood management. Blood Transfus 2012; 10: 5-7.
7. Auerbach M, Macdougall I. Safety of intravenous iron formulations: facts and folklore. Blood Transfus 2014; 12: 296-300.
8. Auerbach M, Kane R. Caution in making references from FDA's adverse event reporting system [letter]. Am J Health System Pharmacy, 2012; 11: 922-3.
9. U. S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) (formerly AERS). Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default. htm, accessed on 06/06/2014.
10. Liumbruno GM, Grazzini G. Double bull's eye for postoperative intravenous iron in patient blood management: better outcome and cost-effective. Blood Transfus 2014; 12: 7-9.
11. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. 28 June 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2013/06/ WC500144874.pdf. Accessed on 06/06/2014.
12. Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163: 303-14.
13. Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth 2014; 14: 115.
14. Muñoz M, Gómez-Ramírez S, Martín- Montañez E, et al. Perioperative intravenous iron: an upfront therapy for treating anaemia and reducing transfusion requirements. Nutr Hosp 2012; 27: 1817-36.
15. Leal-Noval SR, Muñoz M, Asuero M, et al. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus 2013; 11: 585-610.
16. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013; 24: 475-82.
17. Kulnigg-Dabsch S, Evstatiev R, Dejaco C, Gasche C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One 2012; 7: e34520.
18. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369: 1502-4. (Pubitemid 46670290)
19. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008; 83: 580-8. (Pubitemid 351874877)